Prednisone in COPD exacerbation requiring ventilatory support: An open-label randomised evaluation

European Respiratory Journal

Volumn 43, Issue 3, 2014, Pages 717-724

  Abroug, Fekri ^a,b   Ouanes Besbes, Lamia ^a,b   Fkih Hassen, Mohamed ^b,c   Ouanes, Islem ^a,b   Ayed, Samia ^b,c   Dachraoui, Fahmi ^a,b   Brochard, Laurent ^d   ElAtrous, Souheil ^b,c  

^a FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^b Laboratoire de Recherche LR12SP15 Recherche Cardiopulmonaire en Medecine Intensive et Toxicologie Ministère de l'Enseignement Supérieur et de la Recherche Scientifique   (Tunisia)

^c University Hospital   (Tunisia)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; PREDNISONE; TERBUTALINE;

ADD ON THERAPY; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MORTALITY; MULTICENTER STUDY; NONINVASIVE VENTILATION; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT FAILURE;

ADMINISTRATION, ORAL; AGED; ANOXIA; ANTI-INFLAMMATORY AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERGLYCEMIA; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION, ARTIFICIAL; RESPIRATORY FUNCTION TESTS; RISK; SMOKING; TIME FACTORS; TREATMENT OUTCOME; TUNISIA;

EID: 84895547352     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00002913     Document Type: Article

References (38)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2013. www.goldcopd.org Date last accessed: July 2, 2013.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
3. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786-796.
4. Celli BR, MacNee W. ATS/ERS Task Force Report: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
5. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
6. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959-967.
7. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23: 28-33.
8. Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating COPD in the United States. Chest 2001; 119: 344-352.
9. Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proc Am Thorac Soc 2006; 3: 218-221.
10. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
11. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 2007; 14: Suppl. B, 5B-32B.
12. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29: 527-534.
13. Fujimoto K, Yasuo M, Urushibata K, et al. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005; 25: 640-646.
14. Sayiner A, Aytemur ZA, Cirit M, et al. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001; 119: 726-730.
15. Pizzichini MM, Pizzichini E, Efthimiadis A, et al. Asthma and natural colds. Inflammatory indices in induced sputum: a feasibility study. Am J Respir Crit Care Med 1998; 158: 1178-1184.
16. Wood-Baker R, Walters J, Walters EH. Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews. Respir Med 2007; 101: 371-377.
17. Walters JA, Gibson PG, Wood-Baker R, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; 1: CD001288.
18. Cheng T, Gong Y, Guo Y, et al. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials. Clin Respir J 2012 [In press DOI: 10.1111/crj.12008].
19. Chakrabarti B, Angus RM, Agarwal S, et al. Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax 2009; 64: 857-862.
20. Baker EH, Bell D. Blood glucose: of emerging importance in COPD exacerbations. Thorax 2009; 64: 830-832.
21. Alia I, de la Cal MA, Esteban A, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011; 171: 1939-1946.
22. Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020-2025.
23. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 698-703.
24. Bullard MJ, Liaw SJ, Tsai YH, et al. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med 1996; 14: 139-143.
25. Lindenauer PK, Pekow PS, Lahti MC, et al. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010; 303: 2359-2367.
26. de Jong YP, Uil SM, Grotjohan HP, et al. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007; 132: 1741-1747.
27. Walters JA, Wang W, Morley C, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 10: CD006897.
28. Ram FS, Picot J, Lightowler J, et al. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; 3: CD004104.
29. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646-1652.
30. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-671.
31. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158: 1511-1517.
32. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356: 1480-1485.
33. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-913.
34. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
35. Maggiore SM, Richard JC, Abroug F, et al. A multicenter, randomized trial of noninvasive ventilation with heliumoxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med 2010; 38: 145-151.
36. Esteban A, Ferguson ND, Meade MO, et al. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med 2008; 177: 170-177.
37. Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006; 174: 990-996.
38. Scala R, Nava S, Conti G, et al. Noninvasive versus conventional ventilation to treat hypercapnic encephalopathy in chronic obstructive pulmonary disease. Intensive Care Med 2007; 33: 2101-2108.